H ealthy bone marrow progenitors yield a co-ordinated balance of hematopoietic lineages. This balance shifts with aging toward enhanced granulopoiesis with diminished erythropoiesis and lymphopoiesis, changes which likely contribute to the development of bone marrow disorders in the elderly. In this study, RUNX3 was identified as a hematopoietic stem and progenitor cell factor whose levels decline with aging in humans and mice. This decline is exaggerated in hematopoietic stem and progenitor cells from subjects diagnosed with unexplained anemia of the elderly. Hematopoietic stem cells from elderly unexplained anemia patients had diminished erythroid but unaffected granulocytic colony forming potential. Knockdown studies revealed human hematopoietic stem and progenitor cells to be strongly influenced by RUNX3 levels, with modest deficiencies abrogating erythroid differentiation at multiple steps while retaining capacity for granulopoiesis. Transcriptome profiling indicated control by RUNX3 of key erythroid transcription factors, including KLF1 and GATA1. These findings thus implicate RUNX3 as a participant in hematopoietic stem and progenitor cell aging, and a key determinant of erythroid-myeloid lineage balance.
RUNX3 levels in human hematopoietic progenitors are regulated by aging and dictate erythroid-myeloid balance Introduction
Hematopoietic stem and progenitor cells (HSPC) execute tightly co-ordinated self-renewal and lineage commitment programs that generate a balanced output of peripheral blood cell types. With aging, these programs undergo perturbation resulting in increased numbers and decreased function within the stem cell compartment as well as a shift in the balance of cell types produced -namely, an increased proportion of granulocytes at the expense of erythroid and lymphoid lineages. [1] [2] [3] [4] Thus normal aged mice have diminished peripheral red blood cells and lymphocytes, increased circulating neutrophils and monocytes, and increased sensitivity to granulocyte-colony stimulating factor (G-CSF)-induced leukocytosis and HSPC mobilization. 5, 6 The transplantability of age-related HSPC changes highlights the importance of cell-intrinsic determinants, although micro-environmental factors also exert a critical influence. [7] [8] [9] The transcription factor RUNX3 has been characterized as a participant in neural and lymphocyte development, TGFβ signaling, and solid tumor suppression. [10] [11] [12] [13] [14] Several studies have also demonstrated its repression in aged normal as well as tumor tissues, with the principal mechanism of inactivation being epigenetic alterations, particularly DNA methylation. [15] [16] [17] [18] Emerging data suggest a role in hematopoiesis, with zebrafish and murine loss of function studies revealing progenitor perturbations, although the extent of its role has remained unclear due to redundancy with Runx1. [19] [20] [21] Most notably, induction of hematopoietic Runx3 deletion in mice elicited marrow changes similar to those reported with normal aging: increased marrow colony forming units (CFU) and increased peripheral blood mobilization of CFU by G-CSF treatment. 5, 22 This study shows RUNX3 to be expressed in murine and human HSPC, where it undergoes repression and epigenetic modification during normal aging. HSPC levels of RUNX3 were found to determine developmental potential, with deficiency restricting erythropoiesis at commitment and subsequent stages while fully permitting granulopoiesis. HSPC purified from patients with unexplained anemia of aging manifested RUNX3 deficiency and similar developmental alterations. Changes in HSPC transcriptome due to RUNX3 deficiency suggest a role upstream of the erythroid master regulatory transcription factors KLF1 and GATA1.
Methods

Cell culture
Human CD34
+ expansion medium consisted of Iscove's modified Dulbecco's medium (IMDM) supplemented with bovine serum albumin, insulin and transferrin (BIT) 9500, and 100 ng/mL each of rhTPO, rhSCF, and rhFlt3-l, plus 10 ng/ml rhIL-3. Erythroid medium consisted of IMDM supplemented with BIT 9500, and 4.5 U/mL rhEPO and 25 ng/mL rhSCF. Megakaryocyte medium consisted of IMDM supplemented with BIT 9500, and 40 ng/mL rhTPO, 25 ng/mL rhSCF, and 20 ng/mL rhSDF1-alpha. Granulocyte medium consisted of IMDM supplemented with BIT 9500, and 25 ng/mL rhSCF, 10 ng/mL rhIL-3, and 20 ng/mL rhG-CSF. Colony formation assays were conducted using methylcellulose supplemented with 50 ng/mL rhSCF, 10 ng/mL rhIL-3, 20 ng/mL rhIL-6, 3 U/mL rhEPO, 20 ng/mL rhG-CSF, and 10 ng/mL rhGM-CSF.
Mass cytometry
Cells were stained for viability with 100 mM cisplatin, fixed with 1.6% paraformaldehyde, and stored at -80°C. Thawed samples were barcoded, pooled, and surface stained at room temperature for 30 minutes (min). Cells were then permeabilized with methanol and stained for intercellular antigens for 1 hour (h) at room temperature. Next, cells were incubated with Fluidigm CellID Ir-Intercalator, re-suspended in water with normalization beads, and analyzed on a Fluidigm CyTOF 2. Data were beadnormalized and underwent barcode deconvolution using the debarcoding tool MATLAB standalone executable. 23 Data were inverse hyberbolic sine-transformed using a co-factor of 0.25. FlowSOM was used to construct a self-organizing map, and each cell was assigned a phenocode for every lineage marker using flowType. Each grid point was then immunophenotyped, and cell counts were tabulated to form a hierarchical count table. Differential abundance was tested for using edgeR with a quasi-likelihood framework as specified by the cydarTM package.
RNA-sequencing
RNA was extracted using the QIAgen RNeasy Plus Mini Kit, with added DNA digestion. Samples underwent ribosomal reduction, and sequencing with 100bp, paired-end, and 50 million readdepth parameters on an Illumina HiSeq 2500 machine. Data were processed online at usegalaxy.org. Trimmomatic was used to eliminate low quality sequences from the reads, followed by alignment to the hg19 reference genome using HISAT2, and RmDup to eliminate PCR duplicates. Differential gene expression was assessed with both DESeq2 and Cufflinks tools. The Synergizer tool was used to convert UCSC gene identifiers into hgnc gene symbols. 
Unexplained anemia of the elderly studies
CD45RA
-. Colony assays were performed using complete methylcellulose with 12-14 days incubation. For microarray, RNA samples were quantified, subjected to reverse transcription, underwent two rounds of linear amplification, and biotinylated. 15 µg of RNA per sample was assayed using Affymetrix HG U133 Plus 2.0 microarrays. Data were analyzed using the gene expression commons platform.
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Results
Hematopoietic stem cell RUNX3 levels decline with aging
Prior reports have shown marrow-specific Runx3 knockout to elicit aspects of the aging phenotype and to exaggerate the myeloid skewing associated with aging. 5, 22 We therefore assessed RUNX3 expression in rigorously purified human and murine hematopoietic stem cells. In humans, RNA-seq has been conducted on Lin + later stage progenitors also showed diminished RUNX3 expression with aging, indicating that the changes are not HSC-restricted (Online Supplementary Figure S1A ). Evidence for an aging-associated decline in progenitor protein levels was seen in human marrow samples immunostained for RUNX3 (Online Supplementary Figure S1B ). Analysis of murine bone marrow single-cell RNA-seq datasets 24 (GSE89754) from animals with or without erythropoietin (EPO) treatment confirmed that the signals for Runx3 expression came from multipotent and early committed erythroid progenitors rather than contaminant lymphocytes. Discrimination of HSC versus MPP compartments is not possible by this approach (Online Supplementary Figure S1C) .
Because epigenetic changes occur with HSC aging and participate in regulation of RUNX3, [25] [26] [27] we investigated the effect of aging on DNA and histone modifications within the murine and human loci. Analysis of comprehensive DNA methylation mapping by whole genome bisulfite sequencing 3 (GSE47819) revealed significant increases in P2 promoter methylation in aged murine HSC ( Figure 1C RUNX3 in aging and erythroid-myeloid balance haematologica | 2020; 105 (4) 907 
RUNX3 in human hematopoietic stem and progenitor cells participates in erythroid programming
The decline in HSC RUNX3 levels with aging illustrated in Figure 1A Figure S2A) . Immunofluorescent staining revealed predominantly cytoplasmic localization in the undifferentiated cells and enhanced nuclear localization associated with erythroid differentiation (Online Supplementary Figure S3) . Transduction of HSPC with empty or RUNX3-targeting lentiviral shRNA vectors did not alter the localization of RUNX3 in erythroid differentiated cells. Both nuclear and cytoplasmic patterns of RUNX3 localization have been observed in prior studies, and may reflect SMAD or STAT activation status as previously described. [29] [30] [31] [32] Partial knockdown of RUNX3 with three independent lentiviral short RNA hairpins blocked erythroid differentiation of CD34 + progenitors, preventing expression of glycophorin A (CD235a) (Figure 2A and Online Supplementary Figure S2B) . Subsequent experiments employed short hairpin #4 due to robust knockdown (approx. 60% protein loss) with no significant cross-inhibition of other RUNX proteins (Online Supplementary Figure S2C) . As additional controls, CD34
+ progenitors also underwent transduction with shRNA vectors targeting GFP, which had no effect on erythroid differentiation, and RUNX1, which slightly enhanced erythroid differentiation as described 33 (Online Supplementary Figure S2D and E). RUNX3 deficiency in CD34 + HSPC also blocked erythroid colony formation in semi-solid medium, with no significant impact on monocyte or mixed granulocyte-monocyte colonies ( Figure 2B) . As with the colony assays, RUNX3 deficiency caused minimal changes in granulocyte differentiation (CD15) after eight days of suspension culture ( Figure 2C ). When maintained in uni-lineage, serum-free erythroid medium containing EPO and stem cell factor (SCF), RUNX3-deficient progenitors showed time-dependent declines in proliferation and viability ( Figure 2D and E) . By contrast, RUNX3-deficient progenitors cultured in expansion medium with SCF, IL-3, thrombopoietin (TPO), and Flt3-ligand retained normal proliferation and near-normal viability ( Figure 2D and E) . However, RUNX3 knockdown did prevent HSPC upregulation of CD41 in megakaryocytic cultures, suggesting an influence at the level of erythromegakaryocytic progenitors (Online Supplementary Figure  S2F) .
To determine contributions to post-commitment human erythropoiesis, we knocked down RUNX3 in sorted CD36 Conversely, retroviral overexpression of RUNX3 in HUDEP-2 pro-erythroblasts enhanced their hemoglobinization ( Figure 2H and Online Supplementary Figure S2I ).
Progenitor deficiency of RUNX3 alters the balance of lineage output
To analyze in greater detail the effects of RUNX3 deficiency on progenitor fates, mass cytometry (CyTOF) was employed for comprehensive single cell profiling of cells in HSPC expansion culture, and cells in erythroid, megakaryocyte, or granulocyte culture conditions for 48 h. Cells from each culture condition were clustered into populations defined by surface marker staining, followed by construction of minimum spanning tree (MST) plots describing average fold changes in population abundance associated with RUNX3 knockdown ( Figure 3A and Online Supplementary Figure S4A and B). These populations segregated into two main branches: a lower erythromegakaryocytic compartment (Ery/Mk: red oval) defined by CD36 and/or CD41 positivity, and an upper compartment (Myeloid: blue oval) lacking both markers (Online Supplementary Figure S4C and D) . As expected from results in Figure 2 , RUNX3 knockdown selectively diminished cell populations within the Ery/Mk compartment in lineage culture conditions, but not in HSPC expansion conditions ( Figure 3A and Online Supplementary Figure S4A) . This contraction was associated with impaired proliferation, as reflected by decreased Ki-67 expression, but with no evidence of increased apoptosis ( Figure 3B and C) .
Notably, populations in the myeloid compartment (blue oval) were augmented in RUNX3-deficient progenitors grown in erythroid medium but not in other culture conditions. Analysis of these populations revealed a myeloidskewed shift in HSPC distribution, similar to what has been described in aged bone marrow. These populations displayed a GMP (granulocyte-monocyte progenitor) phenotype, based on expression of CD34, CD38, CD123, and CD45RA in various combinations (Online Supplementary  Table S1 ). Strikingly, RUNX3-deficient populations in the Ery/Mk compartment (red oval) exhibited aberrant retention of CD123, as well as global upregulation of the GMP marker CD45RA and the myeloid differentiation antigen CD11b (Figure 3D-F) .
The CyTOF panel permitted assessment of the frequencies of cells with marker profiles of megakaryocyte-erythroid progenitors (MEP), common myeloid progenitors (CMP), and granulocyte monocyte progenitors (GMP). 34 This analysis showed RUNX3 deficiency to decrease MEP frequency and increase CMP and GMP frequencies ( Figure  3G and Online Supplementary Figure S4E) . Within the CMP and MEP compartments, knockdown of RUNX3 was associated with diminished expression of erythroid markers CD36 and CD235a, but enhanced expression of the myeloid marker CD11b ( Figure 3H and I and Online Supplementary Figure S4F ).
RUNX3 deficiency causes perturbations in erythroid transcriptional program
To identify the genes affected by RUNX3 knockdown, we performed mRNA sequencing on undifferentiated
CD34
+ cells and cells in erythroid culture for 24 h, before cell viability was impacted by RUNX3 deficiency. In line with our other data, few changes were found between control and RUNX3-deficient undifferentiated cells (<70 genes with differential expression). However, among the down-regulated genes were key erythroid transcription factors including KLF1, GATA1, and GFI1B ( Figure 4A ). Several globin-and erythroid blood group antigen-encoding genes were decreased as well (data not shown). Notably, Klf1, Gata1, and downstream erythroid target genes Gypa and Epor also underwent downregulation in aged versus young murine HSC ( Figure 4B ). When comparing control and RUNX3-deficient progenitors in erythroid culture, approximately 1,100 genes showed differential expression. These included many of the same genes affected in the undifferentiated cells as well as additional erythroid genes such as CD36 and EPOR ( Figure 4A ). In addition, several granulocytic transcription factors were aberrantly up-regulated, including GFI1, JUN, and FOS ( Figure 4A ). Gene ontology (GO) analysis of genes differentially expressed in control versus RUNX3-deficient undifferentiated progenitors revealed only two significant functional categories, oxygen transport (i.e. erythroid; >100-fold enrichment; FDR 1.22E-6) and blood coagulation (i.e. megakaryocytic; 15.08-fold enrichment; FDR 1.91E-3), both of which showed downregulation. GO analysis of progenitors in erythroid culture yielded similar results but also included genes related to mitochondrial protein synthesis/transport and ribosomal biogenesis ( Figure 4C ).
Hematopoietic stem and progenitor cells RUNX3 deficiency occurs in human anemias associated with aging
Because RUNX3 expression levels strongly influence human erythroid differentiation, its downregulation could potentially contribute to anemias associated with aging. To address this possibility, we analyzed highly purified marrow progenitors from the following subjects: normal non-anemic young (20-35 years old), non-anemic aged (>65 years old), and aged (>65 years old) subjects with unexplained anemia of the elderly (UAE). The diagnosis of UAE was made by ruling out all other potential causes of anemia, as per the criteria of Goodnough and Schrier. 35 Gene expression profiling by microarray confirmed RUNX3 downregulation in UAE versus aged HSC4 (GSE32719) ( Figure 5A ). Functional studies revealed intrinsic differences in lineage output between UAE and non-anemic old progenitors. UAE HSC yielded fewer erythroid colonies (BFU-E) but similar numbers of myeloid colonies (CFU-GM) ( Figure 5B ). These findings resemble the effects of RUNX3 knockdown on colony formation by CD34 + progenitors ( Figure 2B ). Furthermore, UAE MEP also showed poor TGFβ responsiveness in erythroid colony (CFU-E) enhancement ( Figure 5C ), a notable finding given the known influences of HSC aging and RUNX3 expression on this pathway. transcriptional programs affected have been previously linked to RUNX3 function, including quiescence, DNAdamage responsiveness, and TGFβ signaling. 12, 20, 26, 36, 37 Decreased RUNX3 in aged tissues has been previously reported but was analyzed in heterogeneous mixtures of mature cell types. [15] [16] [17] [18] Our results derive from purified, long-lived stem cells and reveal conservation between mice and humans. The repressive mechanism likely relates to the aging-associated epigenetic changes identified. Beerman et al. have shown that murine HSC aging and proliferative stress reconfigure the DNA methylation landscape, with key erythroid and lymphoid regions targeted for hyper-methylation and repression. 6 The increased Runx3 P2 promoter methylation we identified in aged murine HSC has also been found in aging of other tissues and cancers. 16, 27, 38 The aging-associated decreases in H3K27ac that we identified at the human RUNX3 promoter and upstream super-enhancer may contribute to its repression in human HSC.
A feature of HSC aging conserved from mice to humans consists of myeloid skewing characterized by augmented marrow production of neutrophils and monocytes at the expense of erythroid and lymphoid cells. [1] [2] [3] RUNX3 deficiency in aged mice likewise yields increased myelopoiesis; however, it presents as a myeloproliferative disorder, which appears to be distinct from age-associated myeloid skewing due to lack of B-cell and T-cell perturbations, and a relatively mild erythroid deficit that may be secondary to leukocytosis .22 Despite these differences, our study indicates that loss of RUNX3 diminishes the expression of genes required for the erythroid program, and potentially de-represses myeloid genes. Epigenetic and transcriptomic analysis of aged HSC have also indicated that myeloid-skewing may manifest after similar changes. 6, 7 Other aging-like phenotypes of RUNX3 deficiency include expansion of the LSK + HSPC compartment, and increased HSPC mobilization in response to G-CSF. 22 Thus, loss of RUNX3 contributes to age-associated HSPC phenotypes, although likely cooperates with other perturbations to generate bona fide myeloid-skewing.
Additional studies have implicated RUNX3 in non-lymphoid hematopoietic development. In human CD34
+ cell erythroid cultures, RUNX3 was predicted by Cytoscape MiMI analysis of gene expression profiles to be a "parent protein," i.e. a central node, in an erythroid transcription factor network. 39 In zebrafish, morpholino knockdown of runx3 during embryogenesis resulted in severe anemia. 19 Our results define a novel role for RUNX3 in the erythropoietic program, governing the expression of lineage-specific transcription factors such as KLF1, GATA1, and GFI1B. Notably, Klf1 and Gata1 displayed downregulation in aged murine HSC. We further show that RUNX3 deficiency produces perturbations at multiple developmental stages including MEP and committed erythroid progenitors. The decreased proliferation seen in RUNX3-deficient progenitors may contribute to differentiation impairment. However, the retained capacity for myeloid differentiation P. Balogh et al. 912 haematologica | 2020; 105(4) 
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and the aberrant retention of GMP markers such as CD123 and CD45RA on RUNX3 deficient cells suggests an additional role in lineage resolution. Taken together, the current findings implicate RUNX3 in the maintenance of bone marrow lineage balance and identify its decline in aged HSPC as a likely contributory factor in aging-associated anemias.
